American Journal of Clinical Dermatology

, Volume 2, Issue 1, pp 41–47

Cyclosporine in Severe Psoriasis

Results of a Meta-Analysis in 579 Patients
  • Lothar Faerber
  • Matthias Braeutigam
  • Gottfried Weidinger
  • Ulrich Mrowietz
  • Enno Christophers
  • H. J. Schulze
  • G. Mahrle
  • Hans Meffert
  • Sabine Drechsler
Original Research Article

DOI: 10.2165/00128071-200102010-00007

Cite this article as:
Faerber, L., Braeutigam, M., Weidinger, G. et al. Am J Clin Dermatol (2001) 2: 41. doi:10.2165/00128071-200102010-00007

Abstract

Objective

A meta-analysis of 3 major German studies conducted between 1989 and 1994 with cyclosporine in severe psoriasis was performed to allow an integrated evaluation of the efficacy and tolerability of cyclosporine in this indication.

Design and Setting

All 3 studies were prospective, randomized, parallel group studies. The studies were conducted in 61 dermatologic centers in Germany.

Patients and Interventions

The studies involved 597 patients with severe plaque type psoriasis. Treatment consisted of cyclosporine (at a dosage of 1.25, 2.5 or 5 mg/kg/day), etretinate (at a mean daily dose of 0.53 mg/kg/day) or placebo in a total of 756 treatment cycles with a maximum duration of 12 weeks.

Main outcome measures: The main outcome measures were the psoriasis area and severity index (PASI) and

serum creatinine level.

Results

The meta-analysis revealed that cyclosporine given in a dosage of 2.5 and 5 mg/kg/day was significantly superior to etretinate. In addition cyclosporine 1.25 mg/kg/day proved to be significantly more effective than placebo. An increase in serum creatinine level that required intervention occurred in 3.4% of cyclosporine treatment cycles.

Conclusion

Cyclosporine is highly effective and well tolerated in the short term treatment of severe psoriasis.

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Lothar Faerber
    • 1
  • Matthias Braeutigam
    • 2
  • Gottfried Weidinger
    • 2
  • Ulrich Mrowietz
    • 3
  • Enno Christophers
    • 3
  • H. J. Schulze
    • 4
  • G. Mahrle
    • 4
  • Hans Meffert
    • 5
  • Sabine Drechsler
    • 6
  1. 1.Department of PharmacologyUniversity of RegensburgRegensburgGermany
  2. 2.Clinical Research DepartmentNovartis Pharma GmbHNurembergGermany
  3. 3.Department of DermatologyUniversity of KielKielGermany
  4. 4.Department of DermatologyUniversity of CologneCologneGermany
  5. 5.Department of DermatologyCharité Hospital BerlinBerlinGermany
  6. 6.Department of DermatologyUniversity of BonnBonnGermany